My Point is if there is a great pickup truck for sale, that has all the bells and whistles but someone needs a car..they will not buy the pickup due to it being a great pickup truck. Data may be great, but that does not mean a company will buy it. They may have other platforms that take precedence and priority. The only way I can see it being an absolute... if the data is so overwhelmingly commanding and compelling, that HAART looks like pure JUNK..all 96% of it...or even 50%. If HAART is so nasty, why are two companies working on the same compounds ind combination for? In other words, the data needs to represent the 10 super star patients! This delay is fishy and I am concerned they are playing a Stat game as I have alluded to in past posts...Post Hoc, Sub-grouping, Dosing redesigning. We will see. Hopefully, it is simply a logistical or FDA insignificant snag that is out of our control.
News 
Market Data 
Discover 
